← Back to headlines
H.C. Wainwright Reiterates Rating on Bausch & Lomb Based on Pipeline Data
Investment firm H.C. Wainwright maintains its stock rating for Bausch & Lomb, citing recent clinical pipeline developments as key drivers for future valuation.
28 Aug, 11:50 — 28 Aug, 11:50
Sources
Showing 1 of 1 sources
